{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:28:09Z","timestamp":1793550489284,"version":"4.5.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472752"],"award-info":[{"award-number":["82472752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["STAR Protocols"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.xpro.2026.104854","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:07:00Z","timestamp":1790435220000},"page":"104854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol to prepare PARPi-combined LIN28B siRNA nanoparticles and evaluate therapeutic efficacy of malignant ascites"],"prefix":"10.1016","volume":"7","author":[{"given":"Yan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6225","authenticated-orcid":false,"given":"Jianfeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xpro.2026.104854_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202510547","article-title":"PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites","volume":"13","author":"Fang","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xpro.2026.104854_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S2213-2600(19)30373-X","article-title":"Malignant pleural effusion management: keeping the flood gates shut","volume":"8","author":"Walker","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.xpro.2026.104854_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102646","article-title":"Malignant ascites: Current therapy options and treatment prospects","volume":"121","author":"Berger","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xpro.2026.104854_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174318","article-title":"Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response","volume":"13","author":"Rickard","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xpro.2026.104854_bib5","doi-asserted-by":"crossref","first-page":"10575","DOI":"10.21037\/apm-21-2623","article-title":"Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial","volume":"10","author":"Zhou","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.xpro.2026.104854_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xpro.2026.104854_bib7","doi-asserted-by":"crossref","first-page":"842","DOI":"10.21037\/apm-23-554","article-title":"Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment","volume":"13","author":"Ikegami","year":"2024","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.xpro.2026.104854_bib8","first-page":"49","article-title":"The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future","volume":"73","author":"Foster","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xpro.2026.104854_bib9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cell.2010.02.007","article-title":"Lin28: A microRNA regulator with a macro role","volume":"140","author":"Viswanathan","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.xpro.2026.104854_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.tcb.2012.06.001","article-title":"How does Lin28 let-7 control development and disease?","volume":"22","author":"Thornton","year":"2012","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.xpro.2026.104854_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xpro.2026.104854_bib12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"}],"container-title":["STAR Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166726005071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666166726005071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:44:06Z","timestamp":1793547846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666166726005071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2666166726005071"],"URL":"https:\/\/doi.org\/10.1016\/j.xpro.2026.104854","relation":{},"ISSN":["2666-1667"],"issn-type":[{"value":"2666-1667","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protocol to prepare PARPi-combined LIN28B siRNA nanoparticles and evaluate therapeutic efficacy of malignant ascites","name":"articletitle","label":"Article Title"},{"value":"STAR Protocols","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xpro.2026.104854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104854"}}